×
0 0 0.00205761316872424 0 0.0243621399176955 0.0329218106995885 0.037037037037037 0.0493827160493828
Stockreport

The Sad Truth: This Biotech Investing Strategy Almost Always Works [The Motley Fool]

AXOVANT SCIENCES LTD COMMON SHARES (AXON)  More Company Research Source: The Motley Fool
Last axovant sciences ltd common shares earnings: 11/7 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication. Treating disease is a big-money business for pharmaceutical and biotech companies. What was a $1.1 trillion market in 2016 is expected to lead to $1.5 trillion in global drug sales by 2021. With a growing global population and no shortage of diseases left to be treated, investors would think that putting their money to work in drug developers would be a smart idea.  But therein lies the rub: Not all clinical trials prove successful. In fact, a vast majority of hopeful drugs will fall flat on their face at some point during the discovery, laboratory, preclinical, or clinical-testing process. According to Medscape, just one out of every 5,000 to 10,000 drug hopefuls tested in preclinical trials will get the green light from the Food and Drug Administration and find their way to pharmacy shelves.  Image source: Getty Ima [Read more]

IMPACT SNAPSHOT EVENT TIME: AXON
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AXON alerts
from News Quantified
Opt-in for
AXON alerts

from News Quantified
Opt-in for
AXON alerts

from News Quantified